NGL FINECHEM
Quarterly Results Analysis [Dec2024]
NGL FINECHEM Quarterly Results
Consolidated | Dec2024 UnAudited |
Sep2024 UnAudited |
Jun2024 UnAudited |
Mar2024 UnAudited |
Dec2023 UnAudited |
Sep2023 UnAudited |
Jun2023 UnAudited |
Mar2023 UnAudited |
---|---|---|---|---|---|---|---|---|
Revenues | ₹89 Cr | ₹93 Cr | ₹91 Cr | ₹100 Cr | ₹88 Cr | ₹80 Cr | ₹71 Cr | ₹74 Cr |
Expenses | ₹84 Cr | ₹82 Cr | ₹81 Cr | ₹84 Cr | ₹74 Cr | ₹66 Cr | ₹61 Cr | ₹61 Cr |
Operating Income | ₹5 Cr | ₹12 Cr | ₹9 Cr | ₹16 Cr | ₹14 Cr | ₹14 Cr | ₹10 Cr | ₹13 Cr |
Other Income | ₹0 Cr | ₹5 Cr | ₹6 Cr | ₹4 Cr | ₹4 Cr | ₹3 Cr | ₹3 Cr | ₹2 Cr |
Interest | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
Depreciation | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr | ₹3 Cr |
Profit Before Tax | ₹1 Cr | ₹13 Cr | ₹12 Cr | ₹16 Cr | ₹14 Cr | ₹14 Cr | ₹10 Cr | ₹12 Cr |
Profit After Tax | ₹1 Cr | ₹10 Cr | ₹9 Cr | ₹12 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹9 Cr |
EPS | ₹2.07 | ₹15.88 | ₹14.92 | ₹19.95 | ₹16.24 | ₹16.96 | ₹13.77 | ₹15.09 |
Industry Peers & Returns | 1W | 1M | 1Y |
NGL FINECHEM | -4.4% | -10.2% | -53.8% |
SUN PHARMACEUTICAL INDUSTRIES | -1.3% | 4.7% | 3.3% |
DIVIS LABORATORIES | 1.9% | 1.5% | 41.9% |
CIPLA | 3.4% | 0.1% | -3.1% |
TORRENT PHARMACEUTICALS | -4.8% | 1.9% | 20.3% |
DR REDDYS LABORATORIES | -0.1% | -1% | -11.3% |
MANKIND PHARMA | -4% | 4% | -1.9% |
ZYDUS LIFESCIENCES | 0.2% | -2.8% | -15.6% |
LUPIN | -0.1% | -2% | 19.1% |
NGL FINECHEM Quarterly Revenues
Revenues | |
---|---|
Q-o-Q | -4.69 % |
Y-o-Y | 1.30 % |
Quarters | Revenues | % Change | |
---|---|---|---|
Dec2024 | ₹89 Cr | -4.69 | |
Sep2024 | ₹93 Cr | 3.01 | |
Jun2024 | ₹91 Cr | -9.03 | |
Mar2024 | ₹100 Cr | 13.43 | |
Dec2023 | ₹88 Cr | 9.70 | |
Sep2023 | ₹80 Cr | 12.86 | |
Jun2023 | ₹71 Cr | -3.86 | |
Mar2023 | ₹74 Cr | - |
NGL FINECHEM Quarterly Operating Profit
Operating Profit | |
---|---|
Q-o-Q | -55.90 % |
Y-o-Y | -63.25 % |
Quarters | Operating Profit | % Change | |
---|---|---|---|
Dec2024 | ₹5 Cr | -55.90 | |
Sep2024 | ₹12 Cr | 23.60 | |
Jun2024 | ₹9 Cr | -40.90 | |
Mar2024 | ₹16 Cr | 14.09 | |
Dec2023 | ₹14 Cr | -0.72 | |
Sep2023 | ₹14 Cr | 41.63 | |
Jun2023 | ₹10 Cr | -23.97 | |
Mar2023 | ₹13 Cr | - |
Operating Margins | |
---|---|
Q-o-Q | -53.72 % |
Y-o-Y | -63.73 % |
Quarters | Operating Margin% | % Change | |
---|---|---|---|
Dec2024 | 5.72% | -53.72 | |
Sep2024 | 12.36% | 20.00 | |
Jun2024 | 10.3% | -35.06 | |
Mar2024 | 15.86% | 0.57 | |
Dec2023 | 15.77% | -9.47 | |
Sep2023 | 17.42% | 25.50 | |
Jun2023 | 13.88% | -20.96 | |
Mar2023 | 17.56% | - |
NGL FINECHEM Quarterly Profit After Tax
Profit After Tax(PAT) | |
---|---|
Q-o-Q | -86.98 % |
Y-o-Y | -87.26 % |
Quarters | Profit After Tax | % Change | |
---|---|---|---|
Dec2024 | ₹1 Cr | -86.98 | |
Sep2024 | ₹10 Cr | 6.43 | |
Jun2024 | ₹9 Cr | -25.20 | |
Mar2024 | ₹12 Cr | 22.83 | |
Dec2023 | ₹10 Cr | -4.24 | |
Sep2023 | ₹10 Cr | 23.18 | |
Jun2023 | ₹9 Cr | -8.78 | |
Mar2023 | ₹9 Cr | - |
PAT Margins | |
---|---|
Q-o-Q | -86.38 % |
Y-o-Y | -87.47 % |
Quarters | PAT Margin(%) | % Change | |
---|---|---|---|
Dec2024 | 1.43 % | -86.38 | |
Sep2024 | 10.5 % | 3.35 | |
Jun2024 | 10.16 % | -17.73 | |
Mar2024 | 12.35 % | 8.24 | |
Dec2023 | 11.41 % | -12.70 | |
Sep2023 | 13.07 % | 9.19 | |
Jun2023 | 11.97 % | -5.15 | |
Mar2023 | 12.62 % | - |
NGL FINECHEM Quarterly Earnings Per Share (EPS)
EPS | |
---|---|
Q-o-Q | -86.96 % |
Y-o-Y | -87.25 % |
Quarters | EPS | % Change | |
---|---|---|---|
Dec2024 | ₹2.07 | -86.96 | |
Sep2024 | ₹15.88 | 6.43 | |
Jun2024 | ₹14.92 | -25.21 | |
Mar2024 | ₹19.95 | 22.84 | |
Dec2023 | ₹16.24 | -4.25 | |
Sep2023 | ₹16.96 | 23.17 | |
Jun2023 | ₹13.77 | -8.75 | |
Mar2023 | ₹15.09 | - |
You may also like the below Video Courses
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs MANKIND PHARMA LTD